BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iwabu J, Yamashita S, Takeshima H, Kishino T, Takahashi T, Oda I, Koyanagi K, Igaki H, Tachimori Y, Daiko H, Nakazato H, Nishiyama K, Lee YC, Hanazaki K, Ushijima T. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Sci Rep 2019;9:13347. [PMID: 31527639 DOI: 10.1038/s41598-019-50005-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao J, Cao H, Zhang W, Fan Y, Shi S, Wang R. SOX14 hypermethylation as a tumour biomarker in cervical cancer. BMC Cancer 2021;21:675. [PMID: 34098886 DOI: 10.1186/s12885-021-08406-2] [Reference Citation Analysis]
2 Zhang CD, Takeshima H, Sekine S, Yamashita S, Liu YY, Hattori N, Abe H, Yamashita H, Fukuda M, Imamura Y, Ushiku T, Katai H, Makino H, Watanabe M, Seto Y, Ushijima T. Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation. Gastric Cancer 2021. [PMID: 34557982 DOI: 10.1007/s10120-021-01252-y] [Reference Citation Analysis]
3 Xin Q, Han Y, Jiang W, Wang J, Luan Y, Ji Q, Sun W. Genetic susceptibility analysis of FGF5 polymorphism to preeclampsia in Chinese Han population. Mol Genet Genomics 2022. [PMID: 35380267 DOI: 10.1007/s00438-022-01889-z] [Reference Citation Analysis]
4 Yamashita S, Hattori N, Fujii S, Yamaguchi T, Takahashi M, Hozumi Y, Kogawa T, El-Omar O, Liu YY, Arai N, Mori A, Higashimoto H, Ushijima T, Mukai H. Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. Sci Rep 2020;10:15530. [PMID: 32968149 DOI: 10.1038/s41598-020-72661-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]